⌕
Supernus · SUPN · Nasdaq
Tenet 53 · Mixed
Compare
$29.04+0.73%At closeTenet 53 · Mixed
$29.04+0.21 (+0.73%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Supernus (SUPN) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is SUPN's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● GlobeNewsWireNov 10, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London

ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, …

SUPN +0.7% todayRead at source ↗
● BenzingaNov 9, 2026 · 11:30 ET
This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.…

SUPN +0.7% todayRead at source ↗
● Defense WorldNov 6, 2026 · 02:29 ET
Head-To-Head Review: Supernus Pharmaceuticals (NASDAQ:SUPN) and Chugai Pharmaceutical (OTCMKTS:CHGCY)

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) and Supernus Pharmaceuticals (NASDAQ: SUPN - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based…

SUPN +0.7% todayRead at source ↗
● The Motley FoolNov 2, 2026 · 16:43 ET
Why Indivior Pharmaceuticals Stock Topped the Market Today

The peer is Supernus Pharmaceuticals. The combined business will bear the Supernus name and stock ticker under the terms of a deal announced in August.…

SUPN +0.7% todayRead at source ↗
● GlobeNewsWireNov 2, 2026 · 09:18 ETCOMPANY'S OWN WORDS
Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader

ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN)1 today announced the successful completion of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (Indivior…

SUPN +0.7% todayRead at source ↗
● GlobeNewsWireOct 29, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Supernus Announces Third Quarter 2026 Financial Results

ROCKVILLE, Md., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system …

SUPN +0.7% todayRead at source ↗
● GlobeNewsWireOct 29, 2026 · 07:00 ET
Indivior Reports Third Quarter 2026 Financial Results

Q3'26 Total Net Revenue of $ 356 Million, Up 13% YoY Record Quarterly Total SUBLOCADE® Net Revenue of $ 267 Million in Q3'26, Up 22% YoY Record Quarterly Net Income of $ 137 Million and Record Non-GAAP Net Income of $ 16…

SUPN +0.7% todayRead at source ↗
● GlobeNewsWireOct 21, 2026 · 19:45 ETCOMPANY'S OWN WORDS
Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-year 2027 ROCKVILLE, M…

SUPN +0.7% todayRead at source ↗
● Business WireSep 24, 2026 · 17:40 ET
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals,…

SUPN +0.7% todayRead at source ↗
● Business WireAug 29, 2026 · 07:27 ET
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) and Supernus Pharmaceuticals, Inc. Upon closing of the Proposed Trans…

SUPN +0.7% todayRead at source ↗
● Zacks Investment ResearchAug 21, 2026 · 13:40 ET
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026

INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.…

SUPN +0.7% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just SUPN · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.